A B S T R A C T In vitro evidence presently favors a direct osteolytic effect of biologically active vitamin D metabolites. Studies were designed to evaluate the effect of 25-hydroxycholecalciferol (250HD3) on bone collagen and mineral maturation in vivo and its dependence on parathyroid hormone (PTH). After treatment of sham-operated control and parathyroidectomized (PTX) mature rats with either 250HD3 or an oil vehicle for 2 wk, tibial bone mineral-collagen maturation was quantitated by bromoform-toluene density gradient fractionation techniques. Intestinal calcium absorption was measured by in vivo 45Ca transport procedures. In contrast to the control group, the response to 250HD3 of PTX rats was dramatic. Bone mineral and matrix maturation were both accelerated by 250HD3 treatment without concomitant reduction in total bone mineral or collagen content or changes in the intestinal calcium absorption. These observations support the premise that biologically active vitamin D metabolites stimulate bone tissue maturation, and that PTH is not required in this regard.
INTRODUCTION
It has been well established that vitamin D must be metabolized to more polar hydroxylated compounds before exerting its physiological expression on bone and intestine (1) (2) (3) . The initial site of this transformation is the liver wherein the parent vitamin is bydroxylated to 25-hydroxycholecalciferol (250HD3)' (1) . Subsequent transformations by renal mitochondrial 24-and 1-hydroxylating systems have been documented (2, 3) and the 1,25-dihydroxycholecalciferol metabolite (1, 25 (OH)2D3) established as the most potent stimulus for the intestinal absorption of calcium (4) Received for publication 29 October 1974 and in revised form 22 May 1975. 'Abbreziations used in this paper: 1,25 (OH)2D3, 1,25 dihydroxycholecalciferol; 250HD,, 25-hydroxycholecalciferol; Pi, inorganic phosphorus; PTH, parathyroid hormone; PTX, parathyroidectomized. and the in vitro resorption of bone (5) . The exact relationship between the in vitro potency of this dihydroxylated vitamin D metabolite in resorbing relatively immature skeletal tissue (5, 6) and its documented antirachitic in vivo effect is still ill defined and at best conjectural (7) . Moreover, although the effect of parathyroid hormone (PTH) on bone mineral mobilization has been well established, its interaction with vitamin D and/or its metabolites in this regard is still controversial (8) (9) (10) , as is the role it plays in the metabolic transformation of vitamin D to its hydroxylated renal metabolites (11, 12) . This study was designed therefore to evaluate the in vivo effectiveness of 250HD3 on bone metabolism and to determine the role of PTH in this regard.
METHODS
Female Holtzman rats, previously maintained on Purina laboratory chow and tap water, were utilized for all experiments. At 10 wk of age one group of animals was surgically parathyroidectomized under light ether anesthesia, the control group being sham operated. The morning after the operation and after an overnight fast, all rats were bled via the tail vein, and serum was analyzed for total calcium (13), inorganic phosphorus (Pi) (14) , and "5Ca concentrations (15) . Only those animals with serum calcium levels below 8.0 mg/100 ml were considered to be parathyroidectomized (PTX). Thereafter, all PTX animals were maintained on a supplement of 2% calcium lactate in the drinking water. This additional calcium was sufficient to maintain the rat serum calcium concentration in the range of 8.0-9.0 mg/100 ml during the entire experimental period.
24 h after parathyroidectomy one-half of both the PTX and intact control groups were started on a regimen of 250HD3 therapy (500 IU/day) administered orally in oil and continued for the subsequent 14 days. All "control" rats were given an identical volume of oil orally for the 14 days. The animals were bled via the tail vein, after an overnight fast, for calcium (Ca), inorganic phosphorus (Pi), and 4"Ca determinations on 20-,ul portions of plasma, as described above on days 4, 7, and 14 of treatment. At time of sacrifice on day 14, serum samples from all treatment groups were additionally analyzed for levels of 25-OHD3 by the method of Haddad and Chyu (16) .
Those animals with 'Ca bone labels had been injected intraperitoneally 2 37 .0 /ACi 'CaCl2 in saline (New England Nuclear, Boston, Mass.) . Previous studies have demonstrated that after a 2-wk period of labeling most of the retained radioactive calcium can be considered to be in the "stable" as opposed to the "labile and exchangeable" bone calcium pools (17) .
Before sacrifice on day 14 the animals were fasted and placed in metabolic cages for urine collections. Ca and Pi were analyzed as described above. In addition, determinations of urinary hydroxyproline (18) and creatinine (19) were made.
Those animals in which an in vivo measurement of duodenal calcium absorption was to be made according to a modification of Coates and Holdsworth (20) were similarly fasted overnight. On the following day each rat was injected intraduodenally, under light ether anesthesia, with 0.5 1ACi of '5Ca containing 2.0 mg of 4"Ca in 0.1-ml volume. The diluent was isotonic saline. 30 min after injection each animal was bled via the abdominal aorta and serum analyzed for Ca, Pi, and 'Ca as outlined above.
At the time of sacrifice the tibiae were excised, freed of all connective tissue, and washed clean of marrow constituents with isotonic saline. Tibiae were further subjected to bromoform-toluene density gradient fractionation for analyses of the bone mineral-collagen maturational state, as previously described (21) .
In those animals given [3H]proline (100 AtCi), the radioactive isotope was injected intraperitoneally 4 days before sacrifice. At the time of sacrifice the tibiae were cleaned and subjected to bromoform-toluene density gradient fractionation as described above. In addition, a 20-Fil portion of each density fraction was counted on a Packard Tri-Carb liquid scintillation counter (Packard Instrument Co., Downers Grove, Ill.), as previously described (21) . RESULTS Table I , circulating 250HD3 levels were not altered by parathyroidectomy. After the 2-wk experimental period of 250HD3 therapy, no significant altera- (Table II) . There was hypercalciuria despite the lack of significant change in the in vivo duodenal transport of Ca in the 250HD3-treated control animals (Table I) .
As seen in
In contrast to the results obtained in the intact animals, serum Ca rose and Pi fell in the PTX animals during 250HD3 therapy (Table I ). The significant increment in serum Ca and diminution of serum Pi of 250HD3-treated PTX animals obtained despite insignificant changes in urinary Ca and Pi compared to the nontreated PTX animals (Table II) .
For those rats which were given 45Ca parenterally (Table IV) . Density fractionation analysis of the tibiae from PTX rats (Tables V and VI) mature fractions (Tables V and VI) , compared to the untreated PTX group. Furthermore, the maturational profile of the PTX-250HDs tibiae was indistinguishable from that of either the intact or the intact-25OHDs
profiles.
In those animals given [3H]proline for 4 days (Table VII), there was an enhanced incorporation of 'H into the most dense, mature collagen fractions in those bones from 250HD3-treated PTX animals. Concomitantly the total 3H incorporated into the bone was also significantly increased by 4 days.
DISCUSSION
The response to 250HD3 of rats not suffering from a state of vitamin D deficiency and/or hypocalcemia depended on the PTH status of the animal (Table I ).
These observations that 250HD3 administration to intact rats produced no significant alterations in circulating Ca or Pi concentrations despite a marked calciuria (Table II) and unchanged duodenal Ca absorption (Table I) are markedly different from those obtained in the vitamin D-deficient state (4, 6, 7). However, the results of the present study are in agreement (Table I) .
To substantiate whether the calcium mobilization seen in the PTX animals was related to duodenal absorption and/or to bone mineral, a parenteral dose of "5Ca was given 2 wk before parathyroidectomy and 250HD3 therapy. This 'Ca label was thereby incorporated into the "stable" as opposed to "exchangeable" pool of bone mineral (17), an area of bone known to be resorbed by PTH (23) . As early as 4 days after institution of 250HD3 therapy a significantly higher serum calcium level was apparent (Fig. 1) , an elevation which was maintained through1out the 2-wk period. From 7 through 14 days, a significantly higher level of serum 45Ca existed in the 250HD3-treated group and was not accompanied by alterations in`5Ca sp act. Accordingly the data were interpreted to support a (25) .
They are also consistent with in vitro data defining a bone mobilizing effect of both 250HD3 and 1,25 (OH)2Ds (6, 9, 10) . The accumulated data would lead us to believe that biologically active vitamin D metabolites do possess bone resorbing potential in vivo and that this effect is independent of PTH. However, the aforementioned changes in circulating Ca and Pi observed during 250HD3 therapy were not reflected by a change in the tibial Ca or Pi content of the PTX animals (Table III) . The increased Pi concentration of the bones from PTX rats, as compared to values obtained from the controls, is consistent with the elevated serum Pi levels which characterize the parathyroprivic state in rats and with the known influence of the Ca and Pi bathing the mineral upon the composition of the nucleating hydroxyapatite crystals (26, 27) .
Contrary to earlier reports of increased resorption of whole bone by vitamin D metabolites (5, 6, 9) , bone hydroxyproline (collagen) content was significantly elevated in the 25OHD3-treated PTX animals.
The aforementioned serum and bone data interpreted collectively would therefore suggest that total skeletal turnover is increased during 250HD3 therapy with a preferential enhancement of collagen synthesis. The results are consistent with those of Paterson and Fourman (28) and others (29) (30) (31) (32) , wherein vitamin D and/ or its active metabolites were reported to enhance bone collagen synthesis and to stimulate lysyl oxidase activity when administered to hypocalcemic and/or vitamin D-deficient animals. Unlike the vitamin D-deficient animal, however, the serum calciums of the PTX-calcium supplemented animals, although lower than normal, were never at the hypocalcemic levels which have been shown to decrease bone maturation (33) . Rather, the 8.3 mg/100 ml serum calcium, which was maintained in this study (Table I) , was comparable to the serum calcium concentration which Au and Raisz (34) found sufficient to maintain skeletal responsiveness in PTX rats. Thus the 250HD3 effect on bone in the present study cannot be solely a secondary reflection of the reversed hypocalcemia.
It is necessary, however, to reconcile the observed increments in circulating 'Ca and total Ca (Fig. 1) with the unchanged bone Ca, Pi, and "Ca content (Tables III and IV). One might anticipate that in the face of an increased skeletal resorption and an elevated serum calcium, the bone "Ca and total Ca would be diminished. Indeed this would be the case if a significant percentage of the total bone mineral was being resorbed. In fact, the effective 1.2 mg/100 ml increase in the serum Ca of the PTX-250HD3 group compared to the untreated PTX group represents a calculated loss of 0.24 mg of calcium from the entire skeletal tissue or 1.2% of the total bone calcium in the tibiae alone. Thus, the significant elevation observed in the circulating Ca pool as a result of 250HD3 therapy appears to reflect the preferential loss of the available skeletal calcium pool which is beyond chemical quantitation.
To more fully evaluate the bone mineral-matrix composition in the PTX animals and the apparent increase in collagen synthesis observed in the 250HD3-treated animals, density fractionation analysis of the tibiae (Tables V and VI) was performed. The significant increment in the immature bone fractions of the tibiae from PTX rats and the corresponding decrease in the most mature fractions, as compared to control rat bones, reflects the influence of PTH on bone mineral-collagen maturation. In agreement with these data are observations by Burnell et al. (35) , wherein a reduction in the total bone density and a decreased maturation of bone were observed in PTX animals with a significant decrease in hydroxyproline/volume ratio of the bone.
From the profile of the tibiae from the 250HD3-treated PTX animals, additional corroboration was obtained that 250HD3 did not cause a net resorption of bone. In fact, a statistically significant shift of mineral and matrix components occurred from the less dense into the most mature fractions (Table V (Table VII) .
The results of this study do not differentiate between the action of 250HD3 or its 1,25 (OH)2D3 metabolite on bone tissue. Although the ionic control of 1 25 (OH) 2D3 production has proven to be quite complex (37) (38) (39) (40) , one would anticipate that 250HD3 is the primary circulating metabolite in PTX states since both acute (3, 8) (42) .
The observations obtained in this study of PTX animals, however, are consistent with a 250HD3-enhancement of bone maturation and with reported salutory effects of 250HD3 in reversing both the hypocalcemia of hypoparathyroidism (16, 43) and the osteodystrophy of anephric patients (44) . They are also consistent with reported observations that 250HD3 accumulates in the skeleton in abundance (45) . Suffice it to say that these experiments demonstrate that either 250HD3 or other skeletal biologically active metabolites thereof are capable of effecting skeletal turnover in the experimental parathyroprivic, nonrachitic state; and as such the metabolite(s) lead(s) to a restoration of abnormal mineral-collagen profiles to normal.
